Key Points
- CMO Jessica Friedeman sold 15,000 shares on December 9 at an average price of $3.61 for $54,150, reducing her stake by 6.82% to 205,000 shares valued at about $740,050, per an SEC filing.
- LifeMD recently missed quarterly EPS and revenue estimates (EPS -$0.10 vs. -$0.06 expected; revenue $60.17M vs. $62.07M expected), trades near its 1-year low with a $167.3M market cap, and carries a consensus analyst rating of "Hold" with a $9.25 target amid several recent downgrades.
LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CMO Jessica Friedeman sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $3.61, for a total transaction of $54,150.00. Following the sale, the chief marketing officer directly owned 205,000 shares of the company's stock, valued at $740,050. This trade represents a 6.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
LifeMD Price Performance
LFMD stock opened at $3.48 on Friday. The stock has a market capitalization of $167.29 million, a P/E ratio of -20.49 and a beta of 1.36. LifeMD, Inc. has a 1-year low of $3.42 and a 1-year high of $15.84. The business has a fifty day moving average price of $5.13 and a 200-day moving average price of $8.02.
LifeMD (NASDAQ:LFMD - Get Free Report) last issued its earnings results on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04). The business had revenue of $60.17 million during the quarter, compared to analyst estimates of $62.07 million. During the same period last year, the business posted $0.09 earnings per share. As a group, analysts anticipate that LifeMD, Inc. will post -0.56 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have commented on LFMD shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of LifeMD in a research report on Monday. HC Wainwright lowered their target price on LifeMD from $13.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, November 19th. Mizuho reduced their price target on shares of LifeMD from $8.00 to $6.00 and set a "neutral" rating for the company in a research report on Wednesday, November 19th. Wall Street Zen downgraded shares of LifeMD from a "hold" rating to a "sell" rating in a report on Saturday, November 22nd. Finally, Zacks Research cut shares of LifeMD from a "hold" rating to a "strong sell" rating in a report on Thursday, November 20th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $9.25.
Get Our Latest Analysis on LifeMD
Institutional Investors Weigh In On LifeMD
A number of institutional investors have recently added to or reduced their stakes in LFMD. Vanguard Group Inc. boosted its position in shares of LifeMD by 6.7% during the third quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company's stock worth $15,120,000 after acquiring an additional 140,749 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of LifeMD by 5.4% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 981,894 shares of the company's stock worth $5,342,000 after buying an additional 50,600 shares in the last quarter. Geode Capital Management LLC boosted its stake in LifeMD by 7.9% during the second quarter. Geode Capital Management LLC now owns 925,173 shares of the company's stock valued at $12,603,000 after buying an additional 67,440 shares during the last quarter. Royce & Associates LP increased its stake in LifeMD by 5.7% in the 3rd quarter. Royce & Associates LP now owns 814,451 shares of the company's stock worth $5,530,000 after acquiring an additional 44,000 shares during the last quarter. Finally, Jump Financial LLC increased its stake in LifeMD by 205.0% in the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company's stock worth $7,015,000 after acquiring an additional 346,171 shares during the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.
About LifeMD
(
Get Free Report)
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
